APLASTIC ANEMIA AND AGRANULOCYTOSIS
HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF CARBAMAZEPINE. DATA FROM A
POPULATION-BASED CASE-CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING
THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER,
THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW,
APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR
AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR
ALTHOUGH REPORTS OF TRANSIENT OR PERSISTENT DECREASED
PLATELET OR WHITE BLOOD CELL COUNTS ARE NOT UNCOMMON IN ASSOCIATION WITH THE USE
OF CARBAMAZEPINE, DATA ARE NOT AVAILABLE TO ESTIMATE ACCURATELY THEIR INCIDENCE
OR OUTCOME. HOWEVER, THE VAST MAJORITY OF THE CASES OF LEUKOPENIA HAVE NOT
PROGRESSED TO THE MORE SERIOUS CONDITIONS OF APLASTIC ANEMIA OR
BECAUSE OF THE VERY LOW INCIDENCE OF AGRANULOCYTOSIS AND
APLASTIC ANEMIA, THE VAST MAJORITY OF MINOR HEMATOLOGIC CHANGES OBSERVED IN
MONITORING OF PATIENTS ON CARBAMAZEPINE ARE UNLIKELY TO SIGNAL THE OCCURRENCE OF
EITHER ABNORMALITY. NONETHELESS, COMPLETE PRETREATMENT HEMATOLOGICAL TESTING
SHOULD BE OBTAINED AS A BASELINE. IF A PATIENT IN THE COURSE OF TREATMENT
EXHIBITS LOW OR DECREASED WHITE BLOOD CELL OR PLATELET COUNTS, THE PATIENT
SHOULD BE MONITORED CLOSELY. DISCONTINUATION OF THE DRUG SHOULD BE CONSIDERED IF
ANY EVIDENCE OF SIGNIFICANT BONE MARROW DEPRESSION DEVELOPS.
Before prescribing Carbatrol, the physician
should be thoroughly familiar with the details of this prescribing information,
particularly regarding use with other drugs, especially those which accentuate
CARBATROL* is an anticonvulsant and specific analgesic for trigeminal neuralgia,
available for oral administration as 100 mg, 200 mg and 300 mg extended-release
capsules of Carbamazepine, USP. Carbamazepine is a white to off-white powder,
practically insoluble in water and soluble in alcohol and in acetone.
Partial seizures with complex symptomatology (psychomotor, temporal lobe).
Patients with these seizures appear to show greater improvements than those with
Generalized tonic-clonic seizures (grand mal).
Mixed seizure patterns which include the above, or other partial or
generalized seizures. Absence seizures (petit mal) do not appear to be
controlled by carbamazepine (see PRECAUTIONS, General).
Carbatrol is indicated in the treatment of the pain associated
with true trigeminal neuralgia. Beneficial results have also been reported in
glossopharyngeal neuralgia. This drug is not a simple analgesic and should not
be used for the relief of trivial aches or pains.
Media Articles Related to Carbatrol (Carbamazepine)
Epilepsy: Vimpat EU positive monotherapy Phase 3 results
Source: Epilepsy News From Medical News Today [2015.10.08]
UCB has announced positive results of a Phase 3 non-inferiority study designed to compare efficacy and safety of lacosamide to carbamazepine-CR (controlled release; retard tablets) as monotherapy...
Published Studies Related to Carbatrol (Carbamazepine)
Evaluation of the efficacy and safety of pregabalin, venlafaxine, and
carbamazepine in patients with painful diabetic peripheral neuropathy. A
randomized, double-blind trial. 
venlafaxine in patients with painful diabetic neuropathy (PDN)... CONCLUSION: This study showed the efficacy of venlafaxine, pregabalin, and
Population pharmacokinetics of carbamazepine in elderly patients. 
these parameters... CONCLUSIONS: Carbamazepine clearance was not associated with body weight or any
The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. [2011.05]
PURPOSE: There is relatively little known about the effects of new antiepileptic drugs (AEDs) on sleep. This study was done to evaluate the effect of levetiracetam (LEV) on subjective sleep quality and sleep architecture in patients with epilepsy, and the results were compared with the effects of carbamazepine-CR (CBZ-CR)... CONCLUSION: LEV may increase sleep efficiency without major effects on sleep structure with an overall effect on sleep parameters comparable to CBZ-CR. Copyright (c) 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. [2011.02]
By reducing neuronal excitability through selective binding to the alpha(2)delta subunit of voltage-dependent calcium channels, pregabalin effectively treats epilepsy, chronic pain, and anxiety disorders. To evaluate if pregabalin coadministration affects pharmacokinetics of other antiepileptic drugs, population pharmacokinetic analyses using NONMEM software were performed on data from three epilepsy trials involving seven antiepileptic drugs with pregabalin as add-on therapy...
Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. [2011.02]
PURPOSE: Antiepileptic drugs (AEDs) are widely used in reproductive-age women...
Clinical Trials Related to Carbatrol (Carbamazepine)
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency [Recruiting]
The primary objective is to determine if the medication Carbamazepine, can be used as a
therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
Carbamazepine Extended-Release for the Treatment of Bipolar Depression [Completed]
To study the efficacy and safety of beaded extended-release Carbamazepine (Equetro) in the
treatment of patients with Bipolar Disorder with a Major Depressive Episode.
A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir [Completed]
The purpose of this study is to investigate the potential pharmacokinetic (what the body
does to the drug) interactions between multiple doses of phenytoin 200 mg every 12 hours or
carbamazepine 200 mg every 12 hours and telaprevir 750 mg every 8 hours at steady-state
(constant concentration of medication in the blood) in healthy participants.
Fed Bioequivalence Study of CBZ Formulations [Completed]
Controlled release Carbamazepine (CBZ) is a antiepileptic, antineuralgic and mood stabilizer
drug. The CR formulation of CBZ is slowly absorbed and the elimination half life varies
with time due to metabolism autoinduction.
The primary objective of this study is to estimate the bioequivalence of the new brand
generic product (Auration(R) CR) 400 mg manufactured in Uruguay vs. the innovative product
(Tegretol(R) CR) 400 mg manufactured in Brasil, under fed conditions. The secondary
objective will be evaluation of safety issues.
The study design will be randomized two sequences, two periods and crossover. For a power
of not less than 80% sample size was estimated to be 20 healthy male subjects. Products will
be administered with food (high calories/high fat breakfast) after an overnight fast.
Time vs. concentration curves will be built for each subject and formulation and Area Under
Curve (AUC0240) will be estimated using the trapezoid rule, the AUC 0-inf. (from time 0 to
infinity) will be estimated using the formula Cz/Ke, Cmax will be taken from the individual
This parameters will be statistically processed with the WinNonlin 6. 3
Pharmacokinetics/Statistic software in order to prove bioequivalence between the study
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia [Completed]
The purpose of this study was to determine the efficacy and safety of lamotrigine in
patients with trigeminal neuralgia (TGN).
Reports of Suspected Carbatrol (Carbamazepine) Side Effects
Drug Level Below Therapeutic (4),
Optic Neuritis (4),
Influenza Like Illness (4),
Stevens-Johnson Syndrome (4),
Nausea (4), more >>
Page last updated: 2015-10-08